Fig. 2: GENESIS trial efficacy.

a,b, Patients with MM were mobilized with either motixafortide + G-CSF or placebo + G-CSF with the goal of collecting ≥6 × 10⁶ CD34⁺ cells kg^–1. a, The proportion of patients meeting the primary endpoint of collecting to goal within two apheresis days and the key secondary endpoint of collecting to goal in one apheresis day are shown, along with collection rates after three and four apheresis procedures. No patients in the motixafortide + G-CSF arm underwent a fourth apheresis on protocol. The primary endpoint and prespecified secondary efficacy endpoint were analyzed using the CMH test and are presented as OR with two-sided 95% CIs and P values. b, The numbers of PB CD34⁺ cells μl^–1 in each cohort are presented by mobilization day with standard box and whisker plots, where the measure of center is the median value for PB CD34⁺ cells μl^–1 with the exact median value of CD34⁺ cells μl^–1 noted below the x axis by day and cohort; the box represents the interquartile range and lines represent the minimum/maximum (±1.5 × interquartile range). Each patient contributed a single biologically independent sample examined over one independent experiment per sample/patient. Total sample counts associated with motixafortide + G-CSF were: day 0 (n = 80), day 4 (n = 80), day 5 (n = 80), day 6 (n = 11), day 7 (n = 6) and day 8 (n = 0). Total sample counts associated with placebo + G-CSF were: day 0 (n = 39), day 4 (n = 40), day 5 (n = 39), day 6 (n = 32), day 7 (n = 27) and day 8 (n = 17).